Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.
In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.
In the study, the firm will enroll previously treated patients whose tumors are positive for FRα based on IHC testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback